ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 0990 • ACR Convergence 2024

    Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis

    Nidaa Rasheed1, Humzah Iqbal2 and Candice Reyes3, 1UCSF Fresno, Fresno, CA, 2UCSF FRESNO, FRESNO, 3VACCHCS, Fresno, CA

    Background/Purpose: Cirrhosis is associated with a host of complications such as coagulopathy, renal impairment, esophageal varices, peritonitis, and increased mortality. Rheumatoid arthritis (RA) is a…
  • Abstract Number: 1042 • ACR Convergence 2024

    Identifying Patient Priorities for Patient-Reported Outcome Measures in Rheumatoid Arthritis: A Modified Delphi Consensus Study

    Racheal Githumbi1, Steven Katz2, Ania Kania-Richmond1, Kim Giroux3, Yvonne Wallace3, Cheryl Barnabe1, Glen Hazlewood1, C. Allyson Jones2, Amanda Steiman4, Anshula Ambasta1, Diane Lacaille5, Elaine Yacyshyn2, Jessica Widdifield6, Natasha Gakhal7, Tyler Williamson1 and Claire Barber1, 1University of Calgary, Calgary, AB, Canada, 2University of Alberta, Edmonton, AB, Canada, 3Patient Partner, Calgary, AB, Canada, 4Sinai Health System, Toronto, ON, Canada, 5Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, 6Sunnybrook Research Institute / ICES / UofT Institute of Health Policy, Management & Evaluation, Toronto, ON, Canada, 7Women's College Hospital, Toronto, ON, Canada

    Background/Purpose: Patient-reported outcome measures (PROMs) are essential tools for prioritizing patient-centric care and enhancing health system-performance measurement in rheumatology. Effective use of PROMs collected in…
  • Abstract Number: 1249 • ACR Convergence 2024

    Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry

    Shilpa Venkatachalam1, Kelly Gavigan2, Erik Stone3, Angela Degrassi2, Laura Stradford4, David Curtis2, Esteban Rivera5 and Jeffrey Curtis6, 1Global Healthy Living Foundation, New York, NY, 2Global Healthy Living Foundation, Upper Nyack, NY, 3Global Healthy Living Foundation, Upper Nyack, 4Global Healthy Living Foundation, Nyack, NY, 5Global Healthy Living Foundation, Long Island City, NY, 6University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
  • Abstract Number: 1338 • ACR Convergence 2024

    Health Care Utilization and Cost of Herpes Zoster Infection in Patients with Rheumatoid Arthritis, a Retrospective Cohort Study

    Mohammad Movahedi1, Angela Cesta2, Xiuying Li2, Mark Tatangelo3 and Claire Bombardier3, and OBRI investigators, 1Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, 2UHN, Toronto, ON, Canada, 3University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with rheumatoid arthritis (RA) have approximately a twofold increased risk of developing herpes zoster (HZ) compared to the general population. This elevated risk is attributed…
  • Abstract Number: 1354 • ACR Convergence 2024

    The Association of Genetic Variation in PTPN22 and Rheumatoid Arthritis Disease Activity

    Thomas Riley1, Austin Wheeler2, Bryant England2, grant Cannon3, Sauer brian4, Gary Kunkel5, Katherine Wysham6, Beth Wallace7, Rachel Elam8, Paul Monach9, Andreas Reimold10, Gail Kerr11, Isaac Smith12, John Richards13, Iris Lee14, Rui Xiao15, Scott Damrauer15, Michael George15, Ted Mikuls2 and Joshua Baker15, 1Hopsital of the University of Pennsylvania, Philadelphia, PA, 2University of Nebraska Medical Center, Omaha, NE, 3University of Utah and Salt Lake City VA, Salt Lake City, UT, 4Salt Lake City VA/University of Utah, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 7Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, 8Augusta University, Evans, GA, 9VA Boston Healthcare System, Boston, MA, 10Dallas VA Medical Center, Dallas, TX, 11Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 12Duke University Hospital, Durham, NC, 13Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, 14Washington University in St Louis, Saint Louis, MO, 15University of Pennsylvania, Philadelphia, PA

    Background/Purpose: PTPN22 R620W is a common genetic variation that is a known risk factor for the development of autoimmune disease, including rheumatoid arthritis (RA). This…
  • Abstract Number: 1370 • ACR Convergence 2024

    Upadacitinib vs TNFi and Other JAKi Treatment Outcomes in Australian Rheumatoid Arthritis Patients: Descriptive Comparison of Persistence and Effectiveness Using the OPAL Dataset

    Sabina Ciciriello1, Peter Youssef2, Talib Tahir3, Tegan Smith4, Catherine O'Sullivan4, Joanna Leadbetter5, Belinda Butcher5, Miriam Calao6, Nicole Walsh6 and Geoffrey Littlejohn7, 1The University of Melbourne, Melbourne, Victoria, Australia, 2Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia, 3Coburg Rheumatology Service, Coburg, Victoria, Australia, 4OPAL Rheumatology Ltd, Geelong, Victoria, Australia, 5WriteSource Medical Pty Ltd, Lane Cove, New South Wales, Australia, 6AbbVie Pty Ltd, Mascot, New South Wales, Australia, 7Monash University, Clayton, Victoria, Australia

    Background/Purpose: To descriptively compare treatment patterns, persistence and effectiveness of upadacitinib (UPA), other JAK inhibitors (JAKi) and tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis…
  • Abstract Number: 1387 • ACR Convergence 2024

    Olokizumab Effect on Chronic Pain in Rheumatoid Arthritis: Results of the Observational Study

    Andrey Karateev1, Sofia Kuzkina2, Galym Togizbayev3, Elena Polishuk1, Ekaterina Filatova1, Vera Amirdzhanova1, Victoria Khlaboshchina1, Natalia Lapkina4, Andrey Baranov4 and Alexander Lila5, 1V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia, 2R-Pharm, Moscow, Russia, 3Kazakh National Medical University named after Asfendiyarov S, Almaty, Kazakhstan, 4Yaroslavl State Medical University, Yaroslavl, Russia, 5Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation, Moscow, Russia

    Background/Purpose: To evaluate efficacy and safety of olokizumab (interleukin-6 inhibitor) in RA patients with special attention to chronic pain and a signs of central sensitization.Methods:…
  • Abstract Number: 1405 • ACR Convergence 2024

    Perceived Healthcare Discrimination Among Individuals with Musculoskeletal Conditions: A Retrospective Cross-Sectional Analysis

    Titilayo Adeniran1, Bertilia Trieu2, Sandra Goldsmith1 and Laura Robbins1, 1Hospital for Special Surgery (HSS), New York, NY, 2Hospital for Special Surgery, New York, NY

    Background/Purpose: Musculoskeletal conditions, including osteoarthritis (OA), osteoporosis (OP), rheumatoid arthritis (RA), and chronic pain, significantly burden individuals' health and well-being. These conditions often lead to…
  • Abstract Number: 1682 • ACR Convergence 2024

    Early Development of Ocadusertib, a Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor

    Eric Hanson1, Daniel Dairaghi1, Andrew C. Vendel1, Jonathan Sims1, Yasushi Takita1, Lucy Yan2, Andrew Chow2, Simon Shaw2 and esteban S. Masuda2, 1Eli Lilly and Company, Indianapolis, IN, 2Rigel Pharmaceuticals, San Francisco

    Background/Purpose: Receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors are under investigation in chronic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis. Ocadusertib (LY3871801;…
  • Abstract Number: 1846 • ACR Convergence 2024

    Citrullinated Vimentin-reactive Immune-regulatory CD4+CD39+TIGIThi T Cells Expand During Drug Free Remission in HLA-DR Shared-epitope+ ACPA+ Rheumatoid Arthritis

    Amy Anderson1, Henrique de Paula Lemos1, Hendrik Nel2, Sofia Sorbet Santiago1, Fiona Rayner3, Abbie Degnan1, Imogen Wilson1, Julie Diboll1, Jasmine Sim1, Andrew Melville4, Stefan Siebert4, Iain McInnes5, Carl Goodyear4, Catharien Hilkens1, Andrew Filer6, Karim Raza6, Christopher Buckley7, Hugh Reid8, Kenneth Baker1, Arthur Pratt3, Jamie Rossjohn8, Ranjeny Thomas9 and John Isaacs1, 1Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 2Frazer Institute, The University of Queensland, Translational Research Institute, Brisbane, Australia, 3Translational and Clinical Research Institute, NIHR Newcastle Biomedical Research Centre, Newcastle University and The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, England, United Kingdom, 4School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom, 5University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 6Rheumatology Research Group, Institute for Inflammation and Ageing, NIHR Birmingham Biomedical Research Center and Clinical Research Facility, University of Birmingham, Birmingham, United Kingdom, 7Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 8Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, Victoria, Australia, 9University of Queensland, Brisbane, Australia

    Background/Purpose: There is a need for immunotherapy that sustains symptom remission without ongoing need for disease modifying drugs (DMARDs). In a phase 1b trial of…
  • Abstract Number: 1905 • ACR Convergence 2024

    Combining Three Peripheral Biomarkers to Stratify Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk

    Bryant England1, Austin Wheeler1, Brent Luedders1, Michael Duryee1, Halie Frideres2, Katherine Wysham3, grant Cannon4, Gary Kunkel5, Dana Ascherman6, Paul Monach7, Gail Kerr8, Andreas Reimold9, Joshua Baker10, Geoffrey Thiele1 and Ted Mikuls1, 1University of Nebraska Medical Center, Omaha, NE, 2UNMC Department of Rheumatology, Omaha, NE, 3VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, 4University of Utah and Salt Lake City VA, Salt Lake City, UT, 5University of Utah and George E Wahlen VAMC, Salt Lake City, UT, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 7VA Boston Healthcare System, Boston, MA, 8Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, 9Dallas VA Medical Center, Dallas, TX, 10Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Several peripheral biomarkers for RA-associated interstitial lung disease (RA-ILD) have been evaluated to enhance early RA-ILD identification. The MUC5B rs35705950 promoter variant, matrix metalloproteinase-7…
  • Abstract Number: 2121 • ACR Convergence 2024

    Increased Fracture Rates in Patients Continuing Methotrexate After Methotrexate-associated Lower Limb Insufficiency Fractures: A Retrospective Follow-up Study

    Roba Ghossan1, OLIVIER FOGEL2, Christian Roux1 and Karine Briot1, 1COCHIN HOSPITAL, PARIS, France, 2AP-HP, Paris, France

    Background/Purpose: Spontaneous  lower limb insufficiency fractures (LLIF) described under prolonged exposure to low-dose methotrexate are often bilateral, multiple, and recurrent. They share a common pathognomonic…
  • Abstract Number: 2217 • ACR Convergence 2024

    A Significant Alteration in Circulating Endocannabinoid Levels in Rheumatoid Arthritis and Fibromyalgia Syndrome Patients and Its Correlation with Diseases Severity

    Gilad Halpert1, Eri Govrin2, Boris Gilburd3, Shlomo Segev3, Omer Gendelman4, Abdulla Watad5, Yehuda Shoenfeld6, David Meiri7 and Howard Amital8, 1CAHIM SHEBA MEDICAL CENTER, Tel Hashomer, Israel, 2Sheba Medical Center, Sdot Micha, Israel, 3Sheba Medical Center, Ramat-Gan, Israel, 4Sheba Medical Center, Ramat Gan, Israel, 5Tel Hashomer Medical Center, Ramat Gan, Israel, 6sheba medical center , Israel, Ramat Gan, Israel, 7Technion-Israel Institute of Technology, Haifa, Israel, 8Sheba Medical Center, Tel-Hashomer, Israel, Ramat Gan, Israel

    Background/Purpose: Accumulating evidence suggests that medical cannabis therapy might have beneficial therapeutic effects in the fibromyalgia syndrome (FMS) and in difficult-to-treat rheumatoid arthritis (RA) patients.…
  • Abstract Number: 2234 • ACR Convergence 2024

    Pulmonary Damage Biomarkers and Progression of Rheumatoid Arthritis-associated Interstitial Lung Disease in a Prospective Longitudinal Cohort

    Sung Hae Chang1, Yong-Beom Park2, Gregory McDermott3, Misti Paudel4, Keigo Hayashi3, You-Jung Ha5, Jeong Seok Lee6, Min Uk Kim7, Chan Ho Park8, Sang Wan Chung9, Ji-Won Kim10, Jang Woo Ha11, Sung Won Lee12, Eun Ha Kang5, Yeon-Ah Lee13, Jung-Yoon Choe14, Eun Young Lee15 and Jeffrey Sparks16, and the KOrean Rheumatoid Arthritis Interstitial Lung Disease (KORAIL) group, 1Brigham and Women's Hospital/Soonchunhyang University, College of Medicine, Boston, MA, 2Yonsei University College of Medicine, Seoul, Republic of Korea, 3Brigham and Women's Hospital, Brookline, MA, 4Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, 5Seoul National University Bundang Hospital, Seongnam, South Korea, 6Korea Advanced Institute of Science and Technology, KAIST,, Daejeon, Republic of Korea, 7SMG-SNU Boramae Medical Center, Seoul, Republic of Korea, 8Soonchunhyang University College of Medicine,, Cheonan-si, Republic of Korea, 9Kyung Hee University Hospital, Seoul, Republic of Korea, 10Daegu Catholic University School of Medicine, Nam-gu, Daegu, South Korea, 11Yonsei university college of medicine, Seodaemun-gu, Seoul, South Korea, 12Soonchunhyang University Cheonan Hospital, Seoul, South Korea, 13Kyung Hee University Hospital, Seoul, South Korea, 14Catholic University of Daegu School of Medicine, Daegu, Republic of Korea, 153Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea, 16Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA

    Background/Purpose: RA-associated interstitial lung disease (ILD) is a heterogeneous disease with a chronic course and potential for flares. Serum biomarkers are needed to identify those…
  • Abstract Number: 2251 • ACR Convergence 2024

    Stress-Related Neural Activity Measured with FDG-PET/CT Is Associated with Articular Disease Activity, Systemic Inflammation, and Treatment-associated Change in Arterial Inflammation in Rheumatoid Arthritis

    Jon Giles1, Joan Bathon2, Katherine Liao3, Pamela Rist4, Shady Abohashem5, Michael Osborne5, Giovani Civieri5, Zahi Fayad6, Daniel Solomon3 and Ahmed Tawakol7, 1Cedars Sinai Medical Center, Los Angeles, CA, 2Columbia University, New York, NY, 3Brigham and Women's Hospital, Boston, MA, 4Brigham & Women's Hospital/Harvard University, Boston, MA, 5Massachusetts General Hospital/Harvard University, Boston, MA, 6Mount Sinai Medical Center, New York, NY, 7Massachusetts General Hospital/Harvard Medical School, Boston, MA

    Background/Purpose: The amygdala, a limbic structure of the brain’s salience network, links chronic external stressors with downstream effects on the HPA axis and hematopoietic tissues…
  • « Previous Page
  • 1
  • …
  • 19
  • 20
  • 21
  • 22
  • 23
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology